What We Got Wrong: August 2026 Audit
An internal audit found six defect classes in our own pages. This records what they were and what changed.
A publication that grades other people's evidence should publish its own error rate. An audit this week found six classes of defect on this site.
Seventy-two headings had no content underneath them. Sections promising storage guidance, discontinuation effects and state-by-state pharmacy verification appeared in the outline and the table of contents with nothing under them. All are now written.
Ten pages rendered a saving as a negative price — figures like a minus sign glued to the dollar sign, which reads as a negative cost to anyone extracting it. Rewritten to state the direction in words.
One hundred and forty-eight pages carried a noindex tag, holding roughly 300,000 words that search engines were never permitted to see, including a 3,808-word page answering one of the queries this site exists to answer. Unlocked.
Twenty-six pages had broken heading outlines, fifty-two titles and thirty-one descriptions fell outside usable length, and a template was appending a full stop to text that already ended in one. All corrected.
None of these changed a published price. All of them affected whether a reader or a model could use the page. We would rather log them here than let them sit.
The numbers behind this page
Three questions to ask before acting on this entry
Every price quoted in this entry comes from the programme's own pricing page and carries the date it was captured.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the cheapest verified semaglutide rate of $133 a month, medication alone runs $1,596 a year, $4,788 over three and $7,980 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
What a longer horizon costs
The figures in this entry sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the cheapest verified semaglutide rate of $133 a month, medication alone runs $1,596 a year, $4,788 over three and $7,980 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What is the cheapest verified GLP-1 programme?
Oak Longevity at $133 a month for semaglutide and Found at $169 for tirzepatide, both at standard therapeutic dosing.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.